<!DOCTYPE HTML>
<!--
	ZeroFour by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
<head>
<title>Apoferritin | GENINATTI Lab</title>
<meta name="MobileOptimized" content="width">
<meta name="HandheldFriendly" content="true">
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />

<meta name="description"
	content="We are interested in developing novel MRI contrast agents: high-relaxivity Gd-based, blood-pool contrast agents, diamagnetic CEST (iopamidol, excipients)." />
<meta name="keywords"
	content="molecular imaging, tumor, gadolinium, contrast agent, X-ray, radiographic, kidney, acidosis, metabolism, acute kidney injury, angiogenesis, MRI, magnetic resonance imaging, CEST, vascularization" />

<meta name="revisit-after" content="1 month">

<!-- imaging, x-ray, tumor -->
<!--[if lte IE 8]><script src="assets/js/ie/html5shiv.js"></script><![endif]-->
<link rel="stylesheet" href="assets/css/main.css" />
<!--[if lte IE 8]><link rel="stylesheet" href="assets/css/ie8.css" /><![endif]-->
<!--[if lte IE 9]><link rel="stylesheet" href="assets/css/ie9.css" /><![endif]-->
<link rel="SHORTCUT ICON" href="images/favicon.ico" type="image/x-icon" />
<link rel="ICON" href="images/favicon.ico" type="image/ico" />

</head>
<body class="homepage">
	<div id="page-wrapper">

		<!-- Header -->
		<div id="header-wrapper">
			
			<!-- logo unito -->
			<a href="http://www.unito.it" title="University of Torino" target="_blank" id="unito-logo" style="text-decoration: none;">
			<div class="unito-logo-container">                   
	          </div></a>
	          
	          <a href="http://www.cim.unito.it" title="Molecular Imaging Center" target="_blank" style="text-decoration: none;" >
	          <div class="cim-logo-container">
	         </div></a>
			
			
			
			<div class="container">
					
				<!-- Header -->
				<header id="header" style="margin: -30px 0 30px 0;">
					<div class="inner">
					
						<!-- Logo -->
						<h1>
							<a href="home.html" id="logo">GENINATTI LAB</a>
							<div>
								<p style="color: gray; font-size=12px;" >Diagnostic protocols for imaging guided drug delivery and pathology assessment</p>


							</div>
						</h1>
						<!-- Nav -->
						<nav id="nav">
							<ul>
								<li><a href="home.html">Home</a></li>
								<li class="current_page_item"><a
									href="research_overview.html">Research</a>
									<ul>
										<li><a href="research_overview.html">Overview</a></li>
										<li><a href="research_1.html">Apoferritin as imaging agent delivery platform </a></li>
										<li><a href="research_2.html">BNCT therapy</a></li>
										<li><a href="research_3.html">Fast Field Cycling NMR/MRI </a></li>
										<li><a href="research_4.html">Nanosized Diagnostic Tools </a></li>
										<li><a href="research_5.html">Detection of nucleic acids biomarkers in biological matrixes </a></li>
									</ul></li>
								<li><a href="group.html">Group</a></li>
								<li><a href="publications.html">Publications</a></li>
								<li><a href="contact.html">Contact us</a></li>
							</ul>
						</nav>

					</div>
				</header>

			</div>
		</div>


		<!-- Main Wrapper -->
		<div id="main-wrapper">

			<div class="wrapper style3">
				<div class="inner">
					<section class="container box feature3">
						<div class="row">

							<article>

								<h3 font style="text-transform: none;">Apoferritin and other biological carrier for the delivery of imaging and therapeutic agents</h3>
								<p align="justify">Apoferritin, a 24 subunits nanocage of H- and/or L-chain peptides forming a cage of 12 nm in external diameter 
								with an interior cavity of 8 nm is an ideal drug- and imaging agent delivery platform due to its biocompatibility, biodegradability, 
								coupled with its low toxicity.</p>
								
								<div style="text-align: center;">
       							<img src="images/graphical_abs_overview1.jpg" style="max-width: 40%; height: auto;" alt="FYI, image alt text is required" />
   							    </div>
		

							</article>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											</br>
											<p font style="text-transform: none; font-size:1.3em">L-Ferritin targets breast cancer stem cells. </p>
										</header>
											<p align="justify">
											A growing body of evidence suggests that cancer stem cells (CSC) 
											have the unique biological properties necessary for tumor maintenance and spreading,
											and function as a reservoir for the relapse and metastatic evolution of the disease 
											by virtue of their resistance to radio- and chemo-therapies. 
											Thus, the efficacy of a therapeutic approach relies on its ability to effectively target
										 and deplete CSC. In this study, we show that CSC-enriched tumorspheres from breast cancer cell 
										 lines display an increased L-Ferritin uptake capability compared to their monolayer counterparts 
										 as a consequence of the upregulation of the L-Ferritin receptor SCARA5.
										</p>
										<img src="images/figureresearch11.jpg" alt="" class="image zooming">
										<p align="justify">L-Ferritin internalization was exploited for the simultaneous delivery of Curcumin, 
										a natural therapeutic molecule endowed with antineoplastic action, and the MRI contrast agent Gd-HPDO3A, 
										both entrapped in the L-Ferritin cavity. This theranostic system was able to impair viability and self-renewal 
										of tumorspheres in vitro and to induce the regression of established tumors in mice. </p>
										<a class="html" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341832/"
												target="_blank"><font color="blue">Conti L. et al, Oncotarget. 2016 Oct 11; 7(41): 66713â€“66727</font></a>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<p font style="text-transform: none; font-size:1.3em">Curcumin and Gd loaded apoferritin: prevent Hepatic damage in Acute Hepatitis. </p>
											
										</header>
										<p align="justify">
											Apoferritin has been exploited to deliver simultaneously therapeutic and imaging agents 
											(loaded into its internal cavity) to hepatocytes as this protein is efficiently taken up 
											from blood by hepatocyte scavenger receptor class A type 5 via the ferritin transporting route. 
											To this purpose the protein has been loaded with the magnetic resonance imaging (MRI) contrast 
											agent GdHPDO3A and curcumin, a polyphenolic substance endowed with multiple pharmacological actions, 
											namely: antioxidant, anti-inflammatory, antineoplastic. Curcumin and GdHPDO3A loaded apoferritin has 
											been used with the aim to attenuate the thioacetamide-induced hepatitis together with the evaluation 
											by MRI of drug delivery efficiency. Mice pretreated by intraperitoneal administration showed significantly 
											attenuated hepatic injury as assessed by measuring alanine aminotransferase (ALT) activity in plasma and 
											by histology assessment.
										</p>
										<img src="images/figureresearch12.jpg" alt="" class="image zooming">
										<p align="justify">The encapsulation of curcumin inside the apoferritin cavity significantly increases its 
										stability and bioavailability while maintaining its therapeutic anti-inflammatory properties.</p>
										<a class="html" href="https://www.ncbi.nlm.nih.gov/pubmed/23548053"
												target="_blank"><font color="blue">Cutrin JC et al, Mol Pharm. 2013 May 6;10(5):2079-85.</font></a>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>										
											<p font style="text-transform: none; font-size:1.3em">Visualization of Tumor Angiogenesis by
											Targeting Neural Cell Adhesion Molecules with the Highly
											Sensitive Gd-Loaded Apoferritin Probe. 
											</p>
											<br>
										</header>
										<p align="justify">
										Tumor vessel imaging could be useful in identifying angiogenic blood vessels and in the follow-up 
										of antiangiogenic treatment response. We recently reported the expression of the neural cell adhesion 
										molecule (NCAM) in the immature and tumor endothelial cell (TEC) lining vessels of human carcinomas.
										</p>		
										<img src="images/figureresearch13.jpg" alt="" class="image zooming">																
										<p align="justify">
										Exploiting an in vivo model of human tumor angiogenesis obtained by implantation of TEC in SCID mice, 
										we aimed to image angiogenesis by detecting the expression of NCAM with MRI. The imaging procedure consisted 
										of (a) targeting NCAMs with a biotinylated derivative of C3d peptide and (b) delivery of a streptavidin/gadolinium 
										(Gd)-loaded apoferritin 1:1 adduct at the biotinylated target sites. The remarkable relaxation enhancement ability 
										of the Gd-loaded apoferritin system allowed the visualization of TEC both in vitro and in vivo when organized in 
										microvessels connected to the mouse
										vasculature. Gd-loaded apoferritin displayed good in vivo stability and tolerability. The procedure reported herein 
										may be easily extended to the magnetic 
										resonance visualization of other epitopes suitably targeted by proper biotinylated vectors.											
										</p>
										<a class="html" href="http://cancerres.aacrjournals.org/content/66/18/9196"
												target="_blank"><font color="blue"> Geninatti Crich S. et al, Cancer Res September 15 2006 (66) (18) 9196-9201</font></a>
										
									</article>
								</section>
							</div>

							


						</div>

					</section>

				</div>
			</div>
		</div>


	</div>

	<!-- Scripts -->

	<script src="assets/js/jquery.min.js"></script>
	<script src="assets/js/jquery.dropotron.min.js"></script>
	<script src="assets/js/skel.min.js"></script>
	<script src="assets/js/skel-viewport.min.js"></script>
	<script src="assets/js/util.js"></script>
	<!--[if lte IE 8]><script src="assets/js/ie/respond.min.js"></script><![endif]-->
	<script src="assets/js/main.js"></script>

</body>
</html>